{"id":749789,"date":"2023-04-20T16:51:23","date_gmt":"2023-04-20T20:51:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/"},"modified":"2023-04-20T16:51:23","modified_gmt":"2023-04-20T20:51:23","slug":"indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/","title":{"rendered":"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023"},"content":{"rendered":"
\n

NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces\u00a0that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25 \u2013 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally\u2019s) in Las Vegas, NV.<\/p>\n\n\n\n\n
\n Presentation Date:<\/strong>\n <\/td>\nApril 26, 2023<\/td>\n<\/tr>\n
\n Time:\u00a0<\/strong>\n <\/td>\n11:30am Pacific Time<\/td>\n<\/tr>\n
\n Webcast Link:<\/strong>\n <\/td>\n\n https:\/\/www.webcaster4.com\/Webcast\/Page\/2963\/48012<\/a>\n <\/td>\n<\/tr>\n<\/table>\n

Mr. Meckler will be available for one-on-one meetings at the conference venue. To request a meeting and to register for the conference, click here: https:\/\/planetmicrocapshowcase.com\/signup<\/a><\/p>\n

\n About Indaptus Therapeutics<\/strong>\n <\/p>\n

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company\u2019s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus\u2019 patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin\u2019s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy products in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product, with associated \u201ccold\u201d to \u201chot\u201d tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated safe i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product. Indaptus\u2019 Decoy products have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements with the meaning of the Private Securities Litigation Reform Act. These include statements regarding management\u2019s expectations, beliefs and intentions regarding, among other things: our expectations and plans regarding the Phase 1 clinical trial of Decoy20, including the timing and design thereof; the plans and objectives of management for future operations; our research and development activities and costs; the sufficiency of our cash, cash equivalents and marketable securities to fund our ongoing activities; and our assessment of financing options to support our corporate strategy. Forward-looking statements can be identified by the use of forward-looking words such as \u201cbelieve\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cplan\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201ccould\u201d, \u201cmight\u201d, \u201cseek\u201d, \u201ctarget\u201d, \u201cwill\u201d, \u201cproject\u201d, \u201cforecast\u201d, \u201ccontinue\u201d or \u201canticipate\u201d or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption \u201cRisk Factors\u201d included in our most recent Annual Report on Form 10-K filed with the SEC on March 17, 2023, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.<\/p>\n

Contact:\u00a0investors@indaptusrx.com<\/a><\/p>\n

Investor Relations Contact:<\/p>\n

CORE IR
Louie Toma
louie@coreir.com<\/p>\n

CORE IR
Jules Abraham (media)
917-885-7378
julesa@coreir.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces\u00a0that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25 \u2013 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally\u2019s) in Las Vegas, NV. Presentation Date: April 26, 2023 Time:\u00a0 11:30am Pacific Time Webcast Link: https:\/\/www.webcaster4.com\/Webcast\/Page\/2963\/48012 Mr. Meckler will be available for one-on-one meetings at the conference venue. To request a meeting and to register for the conference, click here: https:\/\/planetmicrocapshowcase.com\/signup About Indaptus Therapeutics Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company\u2019s … <\/p>\n

Continue reading “Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-749789","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIndaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces\u00a0that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25 \u2013 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally\u2019s) in Las Vegas, NV. Presentation Date: April 26, 2023 Time:\u00a0 11:30am Pacific Time Webcast Link: https:\/\/www.webcaster4.com\/Webcast\/Page\/2963\/48012 Mr. Meckler will be available for one-on-one meetings at the conference venue. To request a meeting and to register for the conference, click here: https:\/\/planetmicrocapshowcase.com\/signup About Indaptus Therapeutics Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company\u2019s … Continue reading "Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-20T20:51:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023\",\"datePublished\":\"2023-04-20T20:51:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/\"},\"wordCount\":1034,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/\",\"name\":\"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk=\",\"datePublished\":\"2023-04-20T20:51:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/","og_locale":"en_US","og_type":"article","og_title":"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023 - Market Newsdesk","og_description":"NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces\u00a0that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25 \u2013 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally\u2019s) in Las Vegas, NV. Presentation Date: April 26, 2023 Time:\u00a0 11:30am Pacific Time Webcast Link: https:\/\/www.webcaster4.com\/Webcast\/Page\/2963\/48012 Mr. Meckler will be available for one-on-one meetings at the conference venue. To request a meeting and to register for the conference, click here: https:\/\/planetmicrocapshowcase.com\/signup About Indaptus Therapeutics Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company\u2019s … Continue reading \"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-20T20:51:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023","datePublished":"2023-04-20T20:51:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/"},"wordCount":1034,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/","name":"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk=","datePublished":"2023-04-20T20:51:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMjQwNyM1NTM4NzQwIzIyMjIwNjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/indaptus-therapeutics-to-present-at-the-planet-microcap-showcase-vegas-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Indaptus Therapeutics to Present at the Planet\u00a0MicroCap Showcase: VEGAS 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=749789"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749789\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=749789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=749789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=749789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}